Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Giuliano Ramadori, Peter Hohenberger, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Daniel Pink, Justus Duyster, Bengt E. Nilsson, Odd R Monge, Raija Kallio, Petri Bono, Jouni Junnila, Eva Wardelmann, Thor Alvegard, Peter Reichardt
Institutions: University of Helsinki, Helsinki University Hospital, Lund University, Skåne University Hospital, Helios Hospital Berlin-Buch, University of Göttingen, University of Mannheim, University Medical Centre Mannheim, Krankenhaus Nordwest, LMU Klinikum, Essen University Hospital, Helios Hospital Bad Saarow, TUM Klinikum, Sahlgrenska University Hospital, Haukeland University Hospital, Oulu University Hospital, University Hospital Münster
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2432086366